← Eichor
Study identifier: NCT05225311 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Fetal Ebstein Anomaly and Tricuspid Valve Dysplasia Registry

Condition: Ebstein Anomaly · Tricuspid Valve Dysplasia  ·  Sponsor: The Hospital for Sick Children

PhaseN/A
Planned participants1500
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Ebstein anomaly and tricuspid valve dysplasia (EA/TVD) are rare congenital tricuspid valve malformations that carry among the highest mortality of all congenital heart disease diagnosed in utero. Despite the high mortality associated with severe EA/TVD in the fetus, it has only been studied retrospectively. By prospectively enrolling a cohort across multiple centers, many questions may be answered in the perinatal period and beyond. The registry will allow us to understand perinatal and postnatal decision-making in this complex group of patients across centers. Given the rarity of the disease, a retrospective arm was added to the original prospective study in May 2024.

This description comes directly from the study's public registry record.

Talk to the study team

Lindsay Freud, MD  ·  416-813-7500  ·  lindsay.freud@sickkids.ca

Diana Balmer-Minnes, BSc  ·  416-813-7654  ·  diana.balmer-minnes@sickkids.ca

Always discuss trial participation with your own doctor first.

Locations (1)

The Hospital for Sick ChildrenToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05225311